Phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in small cell cancer of the lung.
Nineteen patients with a histologically confirmed diagnosis of small cell carcinoma (SCCL) of the lung were entered on trial with a new nitrosourea, 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU). All patients had had prior chemotherapy and 42% had received a nitrosourea. No patient had a major response to treatment with PCNU and only one patient had a minor response of short duration. Myelosuppression, particularly thrombocytopenia, was the major dose-limiting side effect. PCNU did not appear to be of benefit in patients with recurrent SCCL.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C018627:1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea